Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Employment agreement terminated upon death on April 4, 2026.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Aclaris Therapeutics, Inc.

2012-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Aclaris Therapeutics, Inc.

Open Aclaris Therapeutics, Inc. profile →

Director at Aclaris Therapeutics, Inc.

2012-01-01 → End not stated

current · source reported

Observed: 2026-09-22

Aclaris Therapeuti…Aclaris Therapeutics, Inc.Nathan E. Walker

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingACRS DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open sourceSource 2 · Sec FilingNSTS DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 3 · Sec FilingACRS 10-K executive officersSupports Executive company, Executive title, Other Company Role.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:neal-walker
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board independence · Source reportedNot independent (executive director)1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · CorroboratedServes on the board of Aclaris Therapeutics, Inc.Supported by 3 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board role · Source reportedBoard role: Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
88%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · CorroboratedExecutive at Aclaris Therapeutics, Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at NSTS Bancorp, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Chief Executive Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

Executive title · Source reportedExecutive title: Chief Executive Officer, Chair of the Board of Directors1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: Executive Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Other Company Role · Source reportedNeal Walker is also linked to Aldeyra Therapeutics, Inc. as Director.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Technology background · Under reviewTechnology background: not identified in the cited filing1 source
Verification
Under review
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Under reviewTechnology background reported in filings1 source
Verification
Under review
Confidence
72%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

View all sources6 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Director since · Board independence

  3. https://www.sec.gov/Archives/edgar/data/1557746/000110465926047262/acrs-20260604xdef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Aclaris Therapeutics, Inc. (NASDAQ: ACRS)

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Executive company · Executive title · Other Company Role

  6. https://www.sec.gov/Archives/edgar/data/1557746/000110465926047262/acrs-20260604xdef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership